Tag: analyst

Analysts Anticipate Histogenics Corp to Announce ($0.47) Earnings Per Share (NASDAQ:HSGX)
Financial

Analysts Anticipate Histogenics Corp to Announce ($0.47) Earnings Per Share (NASDAQ:HSGX)

By Jennifer Langley Histogenics Corp (NASDAQ:HSGX) has received an average broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and one has assigned a strong buy rating to the company. Analysts […]

Zimmer Biomet Holdings Receives Average Rating of “Buy” from Analysts (NYSE:ZBH)
Financial

Zimmer Biomet Holdings Receives Average Rating of “Buy” from Analysts (NYSE:ZBH)

By Thomas Dobrow Zimmer Biomet Holdings (NYSE:ZBH) has earned a consensus rating of “Buy” from the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price […]

MiMedx to Webcast Its Analyst Day on October 13, 2015
Recon

MiMedx to Webcast Its Analyst Day on October 13, 2015

MARIETTA, Ga., Sept. 15, 2015 /PRNewswire/ — MiMedx Group, Inc. MDXG, +1.45%the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will be hosting […]

Stock Traders Trading Stocks and Securities
Financial

Oppenheimer: Time To Buy ConforMIS, Two Catalysts Are Coming Next Year Read more

By Monica Gerson In a report published Monday, Oppenheimer analyst Steven Lichtman initiated coverage of ConforMIS Inc CFMS 4.79% with an Outperform rating and a price target of $26. ConforMIS is a commercial-stage orthopedics company currently focusing on implants used in total and partial knee arthroplasty procedures. Analyst Steven Lichtman pointed out, “CFMS’s […]

MERGER SIGN BELOW OFFICE BUILDING
Financial Recon

Analyst: ConMed ripe for M&A spree

By Fink Densford ConMed could be poised for some merger & acquisition activity as new management engineers a turnaround, according to a Wall Street analyst. ConMed (NSDQ:CNMD), in the middle of an under-appreciated turnaround, could be poised to augment its growth via selective acquisitions, according to Leerink Partners analyst Richard […]